Samantha Milton, a social media influencer known as “Smaller Sam PCOS,” has lost 260 pounds after reaching a peak weight of 400 pounds. Milton documented her weight loss journey online, attributing her success to a combination of dietary adjustments, including utilizing fast food options, incorporating GLP-1 medications, and adapting her previous lifestyle.

Milton initially focused on lifestyle changes while also working on her marriage. Her motivation, she stated, was to improve her health “for our kids and each other.” The specifics of her dietary modifications and GLP-1 usage are detailed on her social media platforms, where she shares strategies and encouragement with her followers.

GLP-1 medications, such as semaglutide (Ozempic and Wegovy), are a class of drugs originally designed to treat type 2 diabetes. They work by mimicking a natural hormone that regulates appetite and blood sugar. Their use for weight loss has become increasingly popular, although it's crucial to consult with a healthcare professional before starting any new medication or weight loss program. Milton’s case highlights a growing trend of individuals utilizing these medications alongside lifestyle changes to achieve significant weight loss.

Milton’s online presence, “Smaller Sam PCOS,” focuses on her experiences with polycystic ovary syndrome (PCOS), a hormonal disorder common among women of reproductive age. PCOS can often contribute to weight gain and insulin resistance, making weight management more challenging. Her journey resonates with many women facing similar health challenges, providing a platform for sharing information and support.